Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Biliary Tract Diseases

  Free Subscription


Articles published in Dig Dis

Retrieve available abstracts of 55 articles:
HTML format
Text format



Single Articles


    May 2018
  1. LOOSEN SH, Vucur M, Trautwein C, Roderburg C, et al
    Circulating Biomarkers for Cholangiocarcinoma.
    Dig Dis. 2018 May 15:1-8. doi: 10.1159/000488342.
    PubMed     Text format     Abstract available


    April 2018
  2. SHEN J, Wen T, Li C, Yan L, et al
    The Prognostic Prediction Role of Preoperative Serum Albumin Level in Patients with Intahepatic Cholangiocarcinoma Following Hepatectomy.
    Dig Dis. 2018 Apr 19. pii: 000487479. doi: 10.1159/000487479.
    PubMed     Text format     Abstract available


    May 2017
  3. PENG X, Luo X, Hou JY, Wu SY, et al
    Immunosuppressive Agents for the Treatment of Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis.
    Dig Dis. 2017 May 6. doi: 10.1159/000471874.
    PubMed     Text format     Abstract available


    March 2017
  4. KIM HJ, Kim JS, Oh S, Yoo HS, et al
    Inhibition of Ceramide Decreased the Expression of ATP-Binding Cassette Transporter G5/8 mRNA in an Animal Model of Cholesterol Gallstone.
    Dig Dis. 2017 Mar 8. doi: 10.1159/000465517.
    PubMed     Text format     Abstract available


    January 2017
  5. SLIJEPCEVIC D, van de Graaf SF
    Bile Acid Uptake Transporters as Targets for Therapy.
    Dig Dis. 2017;35:251-258.
    PubMed     Text format     Abstract available


  6. CAI SY, Boyer JL
    The Role of Inflammation in the Mechanisms of Bile Acid-Induced Liver Damage.
    Dig Dis. 2017;35:232-234.
    PubMed     Text format     Abstract available


  7. JOYCE SA, Gahan CG
    Disease-Associated Changes in Bile Acid Profiles and Links to Altered Gut Microbiota.
    Dig Dis. 2017;35:169-177.
    PubMed     Text format     Abstract available


  8. KEPPLER D
    Progress in the Molecular Characterization of Hepatobiliary Transporters.
    Dig Dis. 2017;35:197-202.
    PubMed     Text format     Abstract available


  9. CHANG JC, Beuers U, Oude Elferink RP
    The Emerging Role of Soluble Adenylyl Cyclase in Primary Biliary Cholangitis.
    Dig Dis. 2017;35:217-223.
    PubMed     Text format     Abstract available


  10. DAWSON PA
    Roles of Ileal ASBT and OSTalpha-OSTbeta in Regulating Bile Acid Signaling.
    Dig Dis. 2017;35:261-266.
    PubMed     Text format     Abstract available


  11. PERUGORRIA MJ, Labiano I, Esparza-Baquer A, Marzioni M, et al
    Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment.
    Dig Dis. 2017;35:275-281.
    PubMed     Text format     Abstract available


  12. LARUSSO NF, Tabibian JH, O'Hara SP
    Role of the Intestinal Microbiome in Cholestatic Liver Disease.
    Dig Dis. 2017;35:166-168.
    PubMed     Text format     Abstract available


  13. REICH M, Klindt C, Deutschmann K, Spomer L, et al
    Role of the G Protein-Coupled Bile Acid Receptor TGR5 in Liver Damage.
    Dig Dis. 2017;35:235-240.
    PubMed     Text format     Abstract available


  14. SASAKI M, Nakanuma Y
    Bile Acids and Deregulated Cholangiocyte Autophagy in Primary Biliary Cholangitis.
    Dig Dis. 2017;35:210-216.
    PubMed     Text format     Abstract available


  15. WAHLSTROM A, Kovatcheva-Datchary P, Stahlman M, Backhed F, et al
    Crosstalk between Bile Acids and Gut Microbiota and Its Impact on Farnesoid X Receptor Signalling.
    Dig Dis. 2017;35:246-250.
    PubMed     Text format     Abstract available


  16. HEGADE VS, Jones DE, Hirschfield GM
    Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
    Dig Dis. 2017;35:267-274.
    PubMed     Text format     Abstract available


  17. STEINACHER D, Claudel T, Trauner M
    Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
    Dig Dis. 2017;35:282-287.
    PubMed     Text format     Abstract available


  18. HALILBASIC E, Steinacher D, Trauner M
    Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
    Dig Dis. 2017;35:288-292.
    PubMed     Text format     Abstract available


  19. GALLE PR
    Treating Hepatobiliary Cancers: The Oncology Way.
    Dig Dis. 2017;35:384-386.
    PubMed     Text format     Abstract available


  20. WONG LL, Hegade VS, Jones DEJ
    What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Dig Dis. 2017;35:359-366.
    PubMed     Text format     Abstract available


  21. DUFFY AG, Greten TF
    Treating Hepatobiliary Cancer: The Immunologic Approach.
    Dig Dis. 2017;35:390-396.
    PubMed     Text format     Abstract available


  22. IWAMOTO T, Imai Y, Igura T, Kogita S, et al
    Non-Hypervascular Hypointense Hepatic Nodules during the Hepatobiliary Phase of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI as a Risk Factor of Intrahepatic Distant Recurrence after Radiofrequency Ablation of Hepatocellula
    Dig Dis. 2017;35:574-582.
    PubMed     Text format     Abstract available


    June 2016
  23. HALILBASIC E, Fuchs C, Traussnigg S, Trauner M, et al
    Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease.
    Dig Dis. 2016;34:580-588.
    PubMed     Text format     Abstract available


    January 2016
  24. HOGDALL D, O'Rourke CJ, Taranta A, Oliveira DV, et al
    Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma.
    Dig Dis. 2016;34:440-51.
    PubMed     Text format     Abstract available


  25. CHAZOUILLERES O
    Novel Aspects in the Management of Cholestatic Liver Diseases.
    Dig Dis. 2016;34:340-6.
    PubMed     Text format     Abstract available


  26. WEILER-NORMANN C, Lohse AW
    Variant Syndromes of Autoimmune Liver Diseases: Classification, Diagnosis and Management.
    Dig Dis. 2016;34:334-9.
    PubMed     Text format     Abstract available


  27. ARNDTZ K, Hirschfield GM
    The Pathogenesis of Autoimmune Liver Disease.
    Dig Dis. 2016;34:327-33.
    PubMed     Text format     Abstract available


    October 2015
  28. PISCAGLIA F, Iavarone M, Galassi M, Vavassori S, et al
    Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging.
    Dig Dis. 2015;33:735-744.
    PubMed     Text format     Abstract available


    January 2015
  29. KOHLI R, Myronovych A, Tan BK, Salazar-Gonzalez RM, et al
    Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH?
    Dig Dis. 2015;33:440-6.
    PubMed     Text format     Abstract available


  30. TRAUNER M, Halilbasic E, Claudel T, Steinacher D, et al
    Potential of nor -Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
    Dig Dis. 2015;33:433-9.
    PubMed     Text format     Abstract available


  31. MASYUK TV, Masyuk AI, LaRusso NF
    TGR5 in the Cholangiociliopathies.
    Dig Dis. 2015;33:420-5.
    PubMed     Text format     Abstract available


  32. MEZINA A, Karpen SJ
    Genetic contributors and modifiers of biliary atresia.
    Dig Dis. 2015;33:408-14.
    PubMed     Text format     Abstract available


  33. MAILLETTE DE BUY WENNIGER LJ, Hohenester S, Maroni L, van Vliet SJ, et al
    The Cholangiocyte Glycocalyx Stabilizes the 'Biliary HCO3 Umbrella': An Integrated Line of Defense against Toxic Bile Acids.
    Dig Dis. 2015;33:397-407.
    PubMed     Text format     Abstract available


  34. DAWSON PA
    Impact of Inhibiting Ileal Apical versus Basolateral Bile Acid Transport on Cholesterol Metabolism and Atherosclerosis in Mice.
    Dig Dis. 2015;33:382-7.
    PubMed     Text format     Abstract available


  35. RUDLING M, Bonde Y
    Stimulation of apical sodium-dependent bile Acid transporter expands the bile Acid pool and generates bile acids with positive feedback properties.
    Dig Dis. 2015;33:376-81.
    PubMed     Text format     Abstract available


  36. KRONES E, Wagner M, Eller K, Rosenkranz AR, et al
    Bile Acid-induced cholemic nephropathy.
    Dig Dis. 2015;33:367-75.
    PubMed     Text format     Abstract available


  37. GONZALEZ-SANCHEZ E, Firrincieli D, Housset C, Chignard N, et al
    Nuclear receptors in acute and chronic cholestasis.
    Dig Dis. 2015;33:357-66.
    PubMed     Text format     Abstract available


  38. DEVKOTA S, Chang EB
    Interactions between Diet, Bile Acid Metabolism, Gut Microbiota, and Inflammatory Bowel Diseases.
    Dig Dis. 2015;33:351-6.
    PubMed     Text format     Abstract available


  39. RIDLON JM, Kang DJ, Hylemon PB, Bajaj JS, et al
    Gut microbiota, cirrhosis, and alcohol regulate bile Acid metabolism in the gut.
    Dig Dis. 2015;33:338-45.
    PubMed     Text format     Abstract available


  40. KORDES C, Sawitza I, Gotze S, Haussinger D, et al
    Bile acids and stellate cells.
    Dig Dis. 2015;33:332-7.
    PubMed     Text format     Abstract available


  41. KLIEWER SA, Mangelsdorf DJ
    Bile Acids as Hormones: The FXR-FGF15/19 Pathway.
    Dig Dis. 2015;33:327-31.
    PubMed     Text format     Abstract available


  42. JOURDAINNE V, Pean N, Doignon I, Humbert L, et al
    The Bile Acid Receptor TGR5 and Liver Regeneration.
    Dig Dis. 2015;33:319-26.
    PubMed     Text format     Abstract available


  43. REUE K, Lee JM, Vergnes L
    Diet1 is a regulator of fibroblast growth factor 15/19-dependent bile Acid synthesis.
    Dig Dis. 2015;33:307-13.
    PubMed     Text format     Abstract available


  44. PARES A
    Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
    Dig Dis. 2015;33 Suppl 2:125-33.
    PubMed     Text format     Abstract available


  45. VAN BUUREN HR, Lammers WJ, Harms MH, Hansen BE, et al
    Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis.
    Dig Dis. 2015;33 Suppl 2:118-24.
    PubMed     Text format     Abstract available


  46. POUPON R
    Non-Invasive Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cholangitis.
    Dig Dis. 2015;33 Suppl 2:115-7.
    PubMed     Text format     Abstract available


  47. JOPSON L, Jones DE
    Fatigue in Primary Biliary Cirrhosis: Prevalence, Pathogenesis and Management.
    Dig Dis. 2015;33 Suppl 2:109-14.
    PubMed     Text format     Abstract available


  48. BEUERS U, Hubers LM, Doorenspleet M, Maillette de Buy Wenniger L, et al
    IgG4-Associated Cholangitis - A Mimic of PSC.
    Dig Dis. 2015;33 Suppl 2:176-80.
    PubMed     Text format     Abstract available


  49. CORRIGAN M, Hirschfield GM
    Aspects of the Pathophysiology of Primary Biliary Cirrhosis.
    Dig Dis. 2015;33 Suppl 2:102-8.
    PubMed     Text format     Abstract available


  50. HALILBASIC E, Fuchs C, Hofer H, Paumgartner G, et al
    Therapy of Primary Sclerosing Cholangitis - Today and Tomorrow.
    Dig Dis. 2015;33 Suppl 2:149-63.
    PubMed     Text format     Abstract available


  51. BONATO G, Cristoferi L, Strazzabosco M, Fabris L, et al
    Malignancies in Primary Sclerosing Cholangitis - A Continuing Threat.
    Dig Dis. 2015;33 Suppl 2:140-8.
    PubMed     Text format     Abstract available


  52. PONSIOEN CY
    Diagnosis, Differential Diagnosis, and Epidemiology of Primary Sclerosing Cholangitis.
    Dig Dis. 2015;33 Suppl 2:134-9.
    PubMed     Text format     Abstract available


  53. NAIK J, de Waart DR, Utsunomiya K, Duijst S, et al
    ATP8B1 and ATP11C: Two Lipid Flippases Important for Hepatocyte Function.
    Dig Dis. 2015;33:314-8.
    PubMed     Text format     Abstract available


  54. ABU-HAYYEH S, Williamson C
    Progesterone metabolites as farnesoid X receptor inhibitors.
    Dig Dis. 2015;33:300-6.
    PubMed     Text format     Abstract available


  55. HERKEL J
    Regulatory T Cells in Hepatic Immune Tolerance and Autoimmune Liver Diseases.
    Dig Dis. 2015;33 Suppl 2:70-4.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Biliary Tract Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: